Apeiron Investments
hybrid fundWebsite
Fund rating
0.0 / 35
0 published reviews
No per-dimension scores yet.
Published reviews
About
Named directly in the evidence alongside Christian Angermayer in a longevity/deep-tech investor context. OpenDrugs is a proof-of-concept platform for longevity compound intelligence and could fit a thematic deep-tech/longevity investor conversation.